A Kaiser Family Foundation study revealed about one in eight adults in the US say they’re taking a GLP-1 drug such as Ozempic ...

The FDA is requesting that manufacturers of three GLP-1 receptor agonists remove information on risk for suicidal ideation ...

This video explores an unusually low-priced Ford Sierra, looking at its condition, history, and why it was listed for so ...

Novo Nordisk's new chief executive, Mike Doustdar, has told the JPM Healthcare conference that the key to competing in the GLP-1 agonist category for weight loss will be to make the most of cash-pay ...

Tucker Carlson's gaunt appearance sparks Ozempic rumours as weight-loss drugs become mainstream. Explore the latest ...

After a period of diversification, Novo Nordisk is returning to its roots by focusing on the 2 billion people with diabetes, ...

BMO analysts say Eli Lilly is well-positioned to maintain its lead in the ballooning weight loss space, predicting “strengthening leadership in obesity and beyond” as portfolios expand and patient ...

Through Shed’s GLP-1 Weight-Loss Programs, eligible members can now access Wegovy® in both oral and injectable formats, backed by ongoing support and personalized care. In addition to Wegovy®, Shed ...

While the nutritional needs of GLP-1 users are not drastically different from the general population, according to a dietician, the key distinction lies in reduced food intake ...

Health Canada approved last month two  brand names for generic semaglutide products, Plosbrio  and  Poviztra, which contain ...

The past year was one of turbulence and change at Novo Nordisk, and, while the Danish drugmaker still has its work cut out ...

Meanwhile, the FDA has asked manufacturers of flu vaccines to update their labels to include warnings about the risk of ...